US 12,233,048 B2
Sustained release melatonin compositions
Md Ehtesham Reza, Fair Lawn, NJ (US); Vesselin Danailov Miladinov, Denville, NJ (US); and Richard Mark Warrington, Ridgewood, NJ (US)
Assigned to Societe des Produits Nestle S.A., Vevey (CH)
Filed by Société des Produits Nestlé S.A., Vevey (CH)
Filed on Feb. 6, 2024, as Appl. No. 18/434,065.
Application 18/434,065 is a continuation of application No. PCT/EP2023/078064, filed on Oct. 10, 2023.
Claims priority of provisional application 63/455,331, filed on Mar. 29, 2023.
Claims priority of provisional application 63/416,074, filed on Oct. 14, 2022.
Prior Publication US 2024/0173294 A1, May 30, 2024
Int. Cl. A61K 31/4045 (2006.01); A61K 9/00 (2006.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); A61K 47/36 (2006.01); A61K 47/46 (2006.01)
CPC A61K 31/4045 (2013.01) [A61K 9/0056 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01); A61K 47/46 (2013.01)] 18 Claims
 
1. An orally administrable dosage form comprising a composition comprising melatonin encapsulated within a calcium alginate hydrogel, wherein the composition is held within a gel, wherein the gel is formed using starch as a gelling agent, and wherein the weight ratio of the melatonin to the calcium alginate hydrogel is from 5:95 to 15:85,
the dosage form further comprising additional melatonin which is not encapsulated within the calcium alginate hydrogel.